Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Xtant Medical Holdings (XTNT) EBITDA (2016 - 2025)

Xtant Medical Holdings (XTNT) has disclosed EBITDA for 16 consecutive years, with $2.5 million as the latest value for Q3 2025.

  • Quarterly EBITDA rose 167.28% to $2.5 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $6.3 million through Sep 2025, up 145.33% year-over-year, with the annual reading at -$16.8 million for FY2024, 65.33% down from the prior year.
  • EBITDA for Q3 2025 was $2.5 million at Xtant Medical Holdings, down from $4.6 million in the prior quarter.
  • The five-year high for EBITDA was $4.6 million in Q2 2025, with the low at -$3.8 million in Q4 2023.
  • Average EBITDA over 5 years is -$1.0 million, with a median of -$1.6 million recorded in 2023.
  • Peak annual rise in EBITDA hit 270.8% in 2022, while the deepest fall reached 36520.0% in 2022.
  • Over 5 years, EBITDA stood at -$1.9 million in 2021, then soared by 270.8% to $3.3 million in 2022, then tumbled by 216.61% to -$3.8 million in 2023, then skyrocketed by 50.55% to -$1.9 million in 2024, then surged by 235.02% to $2.5 million in 2025.
  • According to Business Quant data, EBITDA over the past three periods came in at $2.5 million, $4.6 million, and $1.1 million for Q3 2025, Q2 2025, and Q1 2025 respectively.